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Background: As the spread of carbapenemase-producing Enterobacteriaceae poses a 
critical threat to public health, rapid detection of carbapenemase genes is urgently re-
quired for prompt initiation of appropriate antimicrobial therapy and infection control. We 
evaluated the performance of Xpert Carba-R v.2 (Cepheid, USA) compared with that of 
culture-based conventional PCR.
Methods: Using the results of 5,479 consecutive clinical rectal swabs, discrepant analysis 
(enriched culture followed by PCR) was performed for all discordant samples (N=100), 
which were Carba-R v.2-positive and culture-negative. 
Results: Among the samples, 206 carbapenemase genes (3.6%) were detected by Carba-
R v.2. The sensitivity and specificity were 95.0% and 98.1%, respectively. The positive 
predictive value (PPV) and negative predictive value (NPV) were 49.0% and 99.9%, re-
spectively. Following discrepant analysis, the PPV increased to 73.5% and the low PPV 
(8.1%) of the 86 non-KPC improved to 48.8%. Among the 105 discrepancies, NDM was 
the most frequently observed (N=56), followed by KPC (N=26), VIM (N=10), IMP (N=8), 
OXA-48 (N=5). The threshold cycle values between discordant vs. concordant and re-
solved groups were significantly different (P <0.001). 
Conclusions: Carba-R v.2 is a rapid and sensitive method for detecting carbapenemase-en-
coding genes compared with culture-based conventional PCR. Most of our discrepant results 
were non-KPC genes. Thus, the clinical significance of the non-KPC positive cases detected 
by Carba-R v.2 should be investigated. This assay would be useful for deciding whether to 
isolate pre-exposed patients in hospital settings, based on the high specificity and NPV.
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INTRODUCTION
The global spread of carbapenem-resistant Enterobacteriaceae 
(CRE) and infections caused by CRE are urgent health issues 
causing high mortality and morbidity; hence, the WHO has iden-
tified CRE as a cause of global concern [1]. Of the carbapenem 
resistance mechanisms, carbapenemase genes on transmissi-
ble plasmid escalate the probability of dissemination. Patient 
monitoring and implementation of appropriate isolation mea-
sures depending on carbapenemase-producing Enterobacteria-
ceae (CPE) isolate colonization or infection status are crucial for 
preventing the spread of CPE, especially on admission and rapid 
inter-facility or inter-ward transfer.
CPE detection using the culture-based reference method is 
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recommended by the US Centers for Disease Control and Pre-
vention (CDC) and takes at least 72 hours [2]. A longer turn-
around time increases medical expenses, as patients with a 
high risk of CPE, such as those with pre-exposure, need to be 
separated. Xpert Carba-R assay v. 2 (Cepheid, Sunnyvale, CA, 
USA) is a multiplex real-time PCR assay that has been up-
graded to detect not only imipenem (IMP)-, Klebsiella pneu-
moniae carbapenemase (KPC)-, New Delhi metallo-β-lactamase 
(NDM)-, Verona integron-mediated metallo-β-lactamase (VIM)-, 
and oxacillinase (OXA)-48-type, but also OXA-48 variants (OXA-
181 and OXA-232) in less than one hour. Most previous studies 
have evaluated the Carba-R (both v.1 and v.2) using limited 
numbers of clinical samples or contrived samples consisting of 
clearly defined carbapenemase-producing organisms [3-6]. 
Therefore, we evaluated the performance of the upgraded ver-




A total of 5,479 (5,379 from Severance Hospital, Seoul, Korea 
and 100 from Ilsan Hospital, Goyang, Korea) rectal swab sam-
ples were collected from high-risk patients who were admitted 
to intensive care units, CPE-exposed patients, or patients who 
were transferred from long-term care facilities to the two general 
hospitals from August 2016 to December 2017. We performed 
both the Carba-R v.2 and culture-based conventional PCR to 
detect five carbapenemase genes (IMP, KPC, NDM, VIM, and 
OXA-48) in all samples. Requested assays were consecutively 
included. Multiple genes in a sample were separately counted 
in the performance comparison of each carbapenemase gene. 
This prospective study was approved by the Institutional Re-
view Board of Severance Hospital (4-2016-1124) and Ilsan Hos-
pital (NHIC-2017-03-005). Informed consent was waived as this 
study did not include any personal information of the patients. 
Carbapenemase gene detection
Xpert Carba-R assay v.2
The assay was conducted according to the manufacturer’s in-
structions within one hour of sample reception. The initially sug-
gested threshold cycle (Ct) value was ≤38. Assay information, 
including Ct value of each sample was collected and reviewed 
to find an optimal Ct value for detecting carbapenemase genes 
by using receiver operating characteristic (ROC) curve.
Fig. 1. Study flow chart and discrepant analysis protocol. 
Abbreviation: TSB, tryptic soy broth.
5,479 samples
Xpert Carba-R positive & 
culture-based conventional 
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Xpert Carba-R positive & 
culture-based conventional 
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(N=100)
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culture-based conventional 
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culture-based conventional 
PCR negative  
(N=5,278)


















Byun JH, et al.
Carbapenemase gene detection by Xpert Carba-R v.2
https://doi.org/10.3343/alm.2020.40.3.209 www.annlabmed.org  211
Culture-based conventional PCR
This method has been considered as the gold standard for de-
tecting carbapenemase genes. The culture-based assay recom-
mended by the US CDC includes overnight enrichment in 5 mL 
of trypticase soy broth (TSB; Becton Dickinson Co., Sparks, MD, 
USA) with a 10 μg ertapenem disk (BBL, Becton Dickinson Co.), 
followed by overnight subculture on a MacConkey agar plate 
(Asan Pharmaceutical, Seoul, Korea) [7]. All colonies within the 
inhibition zone were picked and boiled for 10 min for DNA ex-
traction followed by PCR to detect five carbapenemase genes 
(IMP, KPC, NDM, VIM, and OXA-48), as previously described [8]. 
Discrepant analysis 
We attempted to resolve the discrepant cases as follows (Fig. 1): 
For Carba-R v.2 negative but culture-positive cases, the PCR 
product was confirmed by sequencing using the same primers. 
The sequencing was performed by a commercial sequencing 
service (Macrogen Inc, Seoul, Korea). For culture-negative but 
Carba-R v.2-positive cases, we conducted an additional assay, 
referred to as discrepant analysis. To identify aerobic or anaero-
bic organisms carrying carbapenemase, remaining samples 
stored in a refrigerator (at 4°C for three to four days) were cul-
tured in TSB and thioglycollate broth. Enriched PCR was per-
formed with 20 µL of incubated broth. In cases of negative re-
sults, conventional PCR was conducted again after a five-day 
incubation to detect fastidious bacterial growth. Based on the 
discrepant analysis results, all samples were divided into three 
groups: the concordant group, which showed concordant Carba-
R v.2 and culture results; the resolved group that initially showed 
discrepancy between the two assays, which was resolved follow-
ing discrepant analysis; and the discordant group, which showed 
unresolved discrepancies
Statistical analysis 
The sensitivity, specificity, positive predictive value (PPV), nega-
tive predictive value (NPV) including 95% confidence interval 
were calculated. The weighted Kappa value was calculated to 
compare the two assays. The Ct values of the concordant, re-
solved, and discordant groups were analyzed using the Kruskal-
Wallis test and Mann-Whitney U-test. The median and interquar-
tile range (IQR) were derived from the data summary. P values 
were calculated using Kruskal-Wallis test and designated thresh-
old of significance was 0.05. The Ct value of each gene group 
was analyzed using the Mann-Whitney U-test. ROC curve was 
also analyzed to calculate optimal cut-off Ct value. Statistical anal-
yses were performed using MedCalc Statistical Software version 
18 (MedCalc Software Bvba, Ostend, Belgium; http://www.med-
calc.org; 2018). 
RESULTS
Of 5,479 samples, 206 carbapenemase genes were detected in 
196 samples (3.6%) by Carba-R v.2 (Table 1; Fig. 1). Concordant 
Carba-R v.2 and culture-based conventional PCR results were 
observed for 96 positive and 5,278 negative samples. In total, 
1.8% (100/5,479) of the samples were Carba-R v.2-positive but 
culture-negative, while <0.1% (5/5,479) of samples were Carba-R 
v.2 negative but culture-positive. Carba-R v.2-negative, culture-
positive cases confirmed by sequencing were considered as false 
negative. Of the 100 Carba-R v.2-positive but initially culture-neg-
ative samples, the presence of carbapenemase genes (KPC 
[N=18], NDM [N=28], VIM [N=3], IMP [N=2], OXA-48 [N=2]; 
53 genes in total) was confirmed in 46 samples following anaero-
bic culture supplementation and enriched PCR. In contrast, 52 
samples remained discordant, as the target carbapenemase 
genes were not recovered from the broth culture. We observed 
10 (0.18%) samples harboring multiple carbapenemase types: 
NDM, IMP, and VIM (N=1); KPC and NDM (N=6); KPC and IMP 
(N=1); NDM and OXA (N=1); and KPC and VIM (N=1). 
A total of 653 patients underwent multiple serial assays (two 
[N=501], three [N=123], four [N=16] five [N=9], six [N=3], 
and seven assays [N=1]), and 21 patients had a positive result 
more than once. Of these 21 patients, six patients (one KPC, 
two VIM, and three NDM) were Carba-R v.2-positive but culture-
negative, with high Ct values (median Ct, 37.1); their Carba-R 
v.2 results converted to negative in subsequent assays.
The sensitivity and specificity of the Carba R were 95.0% and 
98.1%, respectively (Table 2). The weighted Kappa value was 
0.63 (0.57–0.70). Following discrepant analysis, the sensitivity 
Table 1. Comparison of overall performance of the Xpert Carba-R 
v.2 and culture-based PCR method
Carbapenemase genes detected with 




   Before discrepant analysis Positive 96 100 196
Negative 5 5,278 5,283
Total 101 5,378 5,479
   After discrepant analysis Positive 144 52 196
Negative 5 5,278 5,283
Total 149 5,330 5,479
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and specificity improved to 96.7% and 99.0%, respectively (Ta-
ble 2). The weighted Kappa value increased to 0.83 (0.79–0.87). 
KPC was the most frequently detected gene type (N=120, 58.3%), 
followed by NDM (N=61, 29.6%), VIM (N=10, 4.9%), IMP 
(N=9, 4.4%), and OXA-48 (N=6, 2.9%). The performance was 
fairly variable according to gene type (Table 2). A total of 95 KPC-
harboring microorganisms were recovered from culture. Klebsi-
ella pneumoniae was the most common species recovered in 
culture (85, 89.4%), followed by Escherichia coli (5, 5.3%), Citro-
bacter freundii (2, 2.3%), Citrobacter koseri (1, 1.0%), and En-
terobacter kobei (1, 1.0%). For NDM, two K. pneumoniae, two 
Citrobacter amalonaticus, and one E. coli strains were recovered. 
Table 2. Sensitivity, specificity, PPV, and NPV according to carbapenemase type with discrepant analysis 
Carbapenemase type (N) % Sensitivity (95% CI) % Specificity (95% CI) % PPV (95% CI) % NPV (95% CI)
Total (206)* At initial analysis 95.0 (88.8–98.4) 98.1 (97.7–98.5) 49.0 (44.0–53.9) 99.9 (99.8–100)
After discrepant analysis 96.7 (92.3–99.0) 99.0 (98.7–99.3) 73.5 (67.8–78.4) 99.9 (99.7–100)
KPC (120) At initial analysis 94.9 (88.6–98.3) 99.6 (99.3–99.7) 79.7 (72.4–85.4) 99.9 (99.8–100)
After discrepant analysis 95.7 (90.3–-98.6) 99.9 (99.7–99.9) 93.3 (87.5–96.6) 99.9 (99.8–99.9)
NDM (61) At initial analysis 100 (47.8–100) 99.0 (98.7–99.2) 8.2 (6.4–10.3) 100
After discrepant analysis 100 (89.4–100) 99.5 (99.3–99.7) 54.1 (44.4–63.5) 99.9 (99.8–99.6)
VIM (10) At initial analysis - 99.8 (99.6–99.9) - 100
After discrepant analysis 100 (29.2–100) 99.9 (99.7–99.9) 30.0 (17.0–47.3) 100
IMP (9) At initial analysis 100 (2.5–100) 99.8 (99.7–99.9) 11.1 (5.9–19.9) 100
After discrepant analysis 100 (29.2–100) 99.9 (99.8–99.9) 33.3 (18.3–52.6) 100
OXA-48 (6) At initial analysis 100 (2.5–100) 99.9 (99.8–100) 16.7 (7.7–32.4) 100
After discrepant analysis 100 (29.2–100) 99.9 (99.8–100) 50 (24.4–75.6) 100
Non-KPC (86)† At initial analysis 100 (59.0–100) 99.6 (99.5–99.7) 8.1 (6.6–9.9) 100
After discrepant analysis 100 (91.6–100) 99.8 (99.7–99.8) 48.8 (41.5–56.2) 100
*The number of positive samples was counted; samples harboring multiple genes were counted as one sample. 
†Non-KPC includes NDM, VIM, IMP, and OXA-48.
Abbreviations: CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; KPC, Klebsiella pneumoniae carbapenemase; NDM, 
New Delhi metallo-β-lactamase; VIM, Verona integron-mediated metallo-β-lactamase; IMP, imipenem; OXA-48, oxacillinase-48. 
Fig. 2. Comparison of number, median Ct value and interquartile range in (A) the concordant group at initial assay (25.4, 22.2–30.9), re-
solved discrepancy group after discrepant analysis (28.5, 22.3–31.7), and discordant groups (52, 35.0, 31.4–37.7) and (B) the concor-
dant (24.4, 22.2–30.1) and discordant (35.5, 29.9–36.0) KPC groups and concordant (32.2, 27.5–34.6) and discordant (34.8, 31.3–36.5) 
NDM groups. 
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Fig. 2. Comparison of number, median Ct value and interquartile range in (A) the concordant 30 
group at initial assay (25.4, 2 .2 – 30.9), resolved discrepancy group after discrepant analysis 31 
(28.5, 22.3 – 31.7), and discordant groups (52, 35.0, 31.4 – 37.7) and (B) the concordant 32 
(24.4, 22.2 – 30.1) and discordant (35.5, 29.9 – 36.0) KPC groups and concordant (32.2, 27.5 33 
– 34.6) and discordant (34.8, 31.3 – 36.5) NDM groups.   34 
Abbreviations: Ct, threshold cycle; KPC, Klebsiella pneumoniae carbapenemase; NDM, New 35 
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For both IMP and OXA, one K. pneumoniae strain was recovered. 
In discrepant cases, NDM was the most frequently observed 
(Carba-R v.2-positive and culture-negative/total Carba-R v.2-pos-
itive, 28/61, 45.9%), followed by KPC (8/120, 1.2%), VIM (7/10, 
70%), IMP (6/9, 66.6%), and OXA-48 (3/6, 50%). We catego-
rized the samples into three groups: concordant, resolved, and 
discordant, as described above, with median Ct values of 25.4, 
28.5, and 35.0, respectively. The Ct values of the three groups 
were statistically different (P <0.001), except for the concordant 
and resolved following discrepant analysis groups (P =0.22; Fig. 
1A). According to carbapenemase type, the difference in Ct value 
was statistically significant for KPC (P =0.003), but not for NDM 
(P =0.265; Fig. 2B). 
ROC curve analysis yielded a Ct value of 28.8 as the optimal 
cut-off for KPC with 72.5% sensitivity and 87.5% specificity, 
when the concordant and resolved groups were considered as 
positive. When this cut-off value was applied to our results, the 
PPV improved to 82.1%. Satisfactory cut-offs were not derived 
for the other carbapenemase genes, owing to the limited num-
ber of assays
DISCUSSION
The spread of carbapenemase genes poses a public health threat, 
increasing the need for a rapid molecular method for carbapen-
emase gene detection [9]. We prospectively evaluated the per-
formance of the newly developed Carba-R v.2 for detection of 
carbapenemase genes compared with culture-based PCR, us-
ing a large number of clinical rectal swab samples. The overall 
performance of Carba-R v.2 was reliable, except for the PPV; 
this could result in unnecessary isolation of patients, causing 
extra medical resource consumption and patient discomfort. 
To achieve effective infection control, PPV, and NPV are im-
portant to assess the positive and negative results of each car-
bapenemase gene detection assay. The lower PPV of Carba-R 
v.2-positive, culture-negative cases might be caused by false 
positive results due to nonspecific binding, lower bacterial load 
in the samples, reduced bacterial viability owing to inappropri-
ate sample collection/transportation, or uncultivable organisms 
harboring carbapenemase genes [10]. To resolve these issues, 
we performed discrepant analysis; 48% (48/100) of the Carba-
R v.2-positive, culture-negative cases converted to culture-posi-
tive. These cases indicate the existence of carbapenemase genes; 
however, the carbapenemase gene-harboring organisms were 
not recovered using the initial culture method. The advantages 
of the molecular method over culture-based reference methods 
in detecting carbapenemase genes are that it is rapid and sen-
sitive. Therefore, culture-based conventional PCR should be 
complemented by a molecular screening assay [11, 12]. 
Interestingly, the Ct values of the concordant vs. discordant 
groups and the resolved vs. discordant groups were statistically 
different (P <0.001), while those of the concordant and resolved 
groups were not statistically different (P =0.22). The concordant 
group had the lowest Ct values, and the discordant group had 
the highest values. This indicates that, although the Carba-R v.2 
is not quantitative, the Ct values can be affected by target gene 
load, bacterial load, variable copy number of the carbapene-
mase-carrying plasmid, and the sample amount inoculated into 
the cartridge [13]. Hence, a low Ct value would be helpful for 
estimating high carbapenemase gene load; caution is warranted 
when ruling out carbapenemase genes in cases of discrepant 
Carba-R v.2 results with a high Ct value, so as to not miss low-
level carbapenemase genes, as reported for another real-time 
PCR evaluation method, Check-Direct CPE (Check-Points, Wa-
geningen, the Netherlands) [14]. That study suggested that a 
modified cut-off Ct value<35 reduced false positives. Based on 
our KPC data, 28.8 was identified as the optimum cut-off for re-
ducing false positives from the culture method following ROC 
curve analysis, with a sensitivity and specificity of 72.5% and 
87.5%, respectively. Satisfactory cut-offs were not derived for 
the other carbapenemase genes, owing to the limited number 
of assays. To overcome low PPV, the modified cut-off was ap-
plied for the simulation with our results. This could reduce false 
positives and unnecessary isolation of patients, but nullify higher 
sensitivity, the most important advantage of the molecular method. 
Lau, et al. [15] demonstrated a 10–100-fold higher limit of 
detection (LOD) for NDM-harboring strains in culture and PCR 
and for VIM in PCR. We observed different performances ac-
cording to carbapenemase gene. The Ct values of the concor-
dant and discordant groups for KPC genes (not including re-
solved) were statistically significantly different (P =0.003); how-
ever, the NDM values were not significant (P =0.265; Fig. 1B). 
Based on the association between Ct value and bacterial load-
ing, other factors, such as gene copy number, should also be 
considered. 
Previous studies have reported higher performance than our 
data [4, 9, 10, 16]. Some studies included contrived samples 
spiked with higher inoculums of previously well-characterized 
carbapenemase genes [4, 9, 16]. Our study represents clinical 
practice more accurately, as it was performed with a large num-
ber of clinical samples. 
Negative conversion of carbapenemase genes in multiple se-
Byun JH, et al.
Carbapenemase gene detection by Xpert Carba-R v.2
214  www.annlabmed.org https://doi.org/10.3343/alm.2020.40.3.209
rial assays could be due to bacterial eradication, technical bor-
derline or low bacterial loading around the lower LOD, or non-
specific false positives. As colonization of carbapenemase gene-
harboring organisms has been reported [10], bacterial eradica-
tion during the short period of this study is not feasible. Further 
studies are required to determine whether these discordant re-
sults represent a false positive result or a pitfall of the methodol-
ogy, which is more sensitive than the culture method. Currently, 
Carba-R v.2-positive and culture-negative patients are consid-
ered negative for carbapenemase genes. In areas of lower prev-
alence, the PPV could be lower. Unfortunately, no guideline has 
been released regarding the use of molecular methods as a ref-
erence, even in low prevalence settings [10]. The clinical impact 
of Carba-R v.2-positive and culture-negative samples should be 
further clarified. In such cases, we suggest a conservative ap-
proach; the patients should be excluded from the carbapene-
mase gene cohort, but kept in isolation. 
The limitation of this study was that only four carbapenemase 
genes other than KPC were examined. In addition, since OXA-
48 and its variants are not prevalent at our institutes, the im-
provement of Carba-R v.2 could not be assayed. Further studies 
with genetically diverse strains are warranted. 
As most of our discrepant results were non-KPC genes, more 
caution is needed for patients who are positive for non-KPC genes. 
However, Carba-R v.2 would be useful for deciding whether to 
quarantine pre-exposed patients in hospital settings, owing to 
the high specificity and NPV. Considering the global increase in 
CPE, Carba-R v.2 would be helpful for rapid detection of car-
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